We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NV9 market cap is 0. The company's latest EPS is AUD and P/E is N/A.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 15.18M | 0 | 0 | 2.31M |
| Operating Income | -12.19M | -5.95M | -25.38M | -20.76M | -27.06M |
| Net Income | -12.47M | -8.42M | -25.01M | -20.47M | -27.32M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 23.06M | 58.09M | 35.89M | 28.09M | 21.59M |
| Total Liabilities | 8.94M | 20.24M | 17.61M | 16.03M | 31.6M |
| Total Equity | 14.13M | 37.85M | 18.28M | 12.05M | -10.02M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -8.81M | -9.11M | -22.76M | -15.16M | -9.58M |
| Investing | N/A | N/A | -2.37M | N/A | N/A |
| Financing | 12.14M | 28.11M | 3.73M | 12.97M | 5.99M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 204.34M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Kazia Therapeutics Limited |
| Address |
three international towers sydney, new south wales 2000 |
| Website | https://www.kaziatherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
